69,337 results match your criteria Systemic Lupus Erythematosus


Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity.

PLoS One 2019 20;14(2):e0212436. Epub 2019 Feb 20.

Department of Education, Faculty of Education Sciences, University of Almería, Almería, Spain.

Objectives: To study the association of different components of physical fitness [flexibility, muscle strength and cardiorespiratory fitness (CRF)] and a clustered fitness score with health-related quality of life (HRQoL) in women with systemic lupus erythematosus (SLE) and to analyze whether participants with high fitness level have better HRQoL.

Methods: This cross-sectional study included 70 women with SLE (aged 42.5; SD 13. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212436PLOS
February 2019

Systemic Autoimmunity in a Patient With CANDLE Syndrome.

J Investig Allergol Clin Immunol 2019 Feb;29(1):75-76

Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18176/jiaci.0338DOI Listing
February 2019

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.

Ann Rheum Dis 2019 Feb 19. Epub 2019 Feb 19.

Department of Medicine, New York University School of Medicine, New York, New York, USA

Background/purpose: To search for a transmissible agent involved in lupus pathogenesis, we investigated the faecal microbiota of patients with systemic lupus erythematosus (SLE) for candidate pathobiont(s) and evaluated them for special relationships with host immunity.

Methods: In a cross-sectional discovery cohort, matched blood and faecal samples from 61 female patients with SLE were obtained. Faecal 16 S rRNA analyses were performed, and sera profiled for antibacterial and autoantibody responses, with findings validated in two independent lupus cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214856DOI Listing
February 2019

Thermophoretic diagnosis of autoimmune diseases based on Escherichia coli with autodisplayed autoantigens.

Anal Chim Acta 2019 May 21;1055:106-114. Epub 2018 Dec 21.

Department of Materials Science and Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-749, South Korea. Electronic address:

The autoimmune diseases systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS) are diagnosed by detection of autoantibodies against Ro and La protein autoantigens, respectively. In this work, the diagnosis of autoimmune diseases SLE and SS was demonstrated using thermophoresis of Escherichia coli with the autodisplayed autoantigens. Ro and La protein autoantigens were autodisplayed by constitutive expression together with a fluorescent protein called tdTomato in the cytosol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aca.2018.12.038DOI Listing

The role of microRNA-16 in the pathogenesis of autoimmune diseases: A comprehensive review.

Biomed Pharmacother 2019 Feb 16;112:108583. Epub 2019 Feb 16.

Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China Three Gorges University, Yichang, Hubei, 443002, China. Electronic address:

MicroRNAs (miRNAs) are a class of small noncoding RNAs that are only 21-25 nt long. Many studies have shown that miRNA dysfunction is closely related to the occurrence and development of diseases. By combining with the 3' noncoding region of target gene mRNA, miRNAs can mediate the degradation or translation inhibition of mRNA and exert a powerful regulation effect on gene expression at the posttranscriptional level, mainly inhibiting the translation or degradation of targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.01.044DOI Listing
February 2019

Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.

Clin Rheumatol 2019 Feb 18. Epub 2019 Feb 18.

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.

Objectives: To assess the renal and non-renal efficacy of mycophenolate mofetil (MMF) in Japanese patients with systemic lupus erythematosus (SLE).

Methods: We conducted a retrospective study to assess the renal and non-renal efficacies of MMF in Japanese patients with systemic lupus erythematosus (SLE). We analyzed 14 patients with lupus nephritis (LN) who were given MMF, and 13 patients who received monthly intravenous cyclophosphamide (IVCY) as induction therapy, and a further 19 patients without LN who were treated with MMF, and 13 patients who took tacrolimus (TAC) to reduce glucocorticoid dosages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04473-wDOI Listing
February 2019

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.

Arthritis Res Ther 2019 Feb 18;21(1):62. Epub 2019 Feb 18.

Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, 171 76, Stockholm, Sweden.

Background: Previous studies and own clinical observations of patients with systemic lupus erythematosus (SLE) suggest that SLE harbors distinct immunophenotypes. This heterogeneity might result in differences in response to treatment in different subgroups and obstruct clinical trials. Our aim was to understand how SLE subgroups may differ regarding underlying pathophysiology and characteristic biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1836-8DOI Listing
February 2019

Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment.

Pediatr Rheumatol Online J 2019 Feb 18;17(1). Epub 2019 Feb 18.

University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.

Background: To develop and test the feasibility and initial effectiveness of the Treatment and Education Approach for Childhood-onset Lupus (TEACH) protocol, a 6-session cognitive behavioral therapy (CBT) intervention for adolescents and young adults (AYA) with childhood-onset systemic lupus erythematosus (cSLE).

Methods: Females with cSLE (n = 14; ages 13-19 years, M = 16.21 years) presenting to a pediatric rheumatology clinic subsequently completed the protocol, which was iteratively modified based on participant/interventionist feedback. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12969-019-0307-8DOI Listing
February 2019

The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies.

Lupus 2019 Feb 18:961203319829825. Epub 2019 Feb 18.

2 Department of Rheumatology, State University of Rio de Janeiro, Brazil.

Objective: To analyze the impact of different classes of lupus nephritis as risk variables for maternal and fetal adverse outcomes in a cohort of pregnant lupus patients.

Methods: This is a cohort study with retrospective and prospective data collection, conducted at the University Hospital of State University of Rio de Janeiro, Brazil, from 2011 to 2016. A total of 147 pregnancies of 137 systemic lupus erythematosus patients of whom 66 had lupus nephritis were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319829825DOI Listing
February 2019

The contributions of socioeconomic status, perceived stress, and depression to disability in adults with systemic lupus erythematosus.

Disabil Rehabil 2019 Feb 18:1-6. Epub 2019 Feb 18.

b Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California Los Angeles , Los Angeles , CA , USA.

Purpose: Psychological and sociodemographic factors contribute to disability in systemic lupus erythematosus. Yet the pathways by which these factors influence disability remain unclear. The objective of this study was to evaluate a model examining socioeconomic status (SES), perceived stress, and depressive symptoms as determinants of lupus-related disability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09638288.2018.1522550DOI Listing
February 2019

Autophagy and immunological aberrations in systemic lupus erythematosus.

Eur J Immunol 2019 Feb 18. Epub 2019 Feb 18.

Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, 100034, People's Republic of China.

Systemic lupus erythematosus (SLE) is a complex autoimmune disease, in which immune defects can occur at multiple points of the cascading auto-aggressive immune reactions, resulting in a striking heterogeneity of clinical presentations. The clinical manifestations of such autoimmune response can be severe:-common manifestations symptoms include rash and renal inflammation progressing to kidney failure. Autophagy, the cellular "self-digestion" process, is a key factor in the interplay between innate and adaptive immunity. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/eji.201847679
Publisher Site
http://dx.doi.org/10.1002/eji.201847679DOI Listing
February 2019
4 Reads

A promising approach to targeting type 1 IFN in systemic lupus erythematosus.

J Clin Invest 2019 Feb 18. Epub 2019 Feb 18.

Division of Rheumatology, Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.

Despite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most clinical trials of new targeted therapies have been met with disappointment. The type I IFN pathway is believed to play an important role in SLE, and the proposed involvement of this pathway helps explain the frustration behind the failure at targeting either IFN-α or the type 1 IFN receptor itself. In this issue of the JCI, Furie et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI127101DOI Listing
February 2019

Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases.

Kidney Int Rep 2019 Feb 19;4(2):196-211. Epub 2018 Nov 19.

Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.

Neutrophil extracellular traps (NETs) are extracellular DNA structures covered with antimicrobial peptides, danger molecules, and autoantigens that can be released by neutrophils. NETs are an important first-line defense mechanism against bacterial, viral, fungal, and parasitic infections, but they can also play a role in autoimmune diseases. NETs are immunogenic and toxic structures that are recognized by the autoantibodies of patients with antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ekir.2018.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365354PMC
February 2019

A Case of Rhupus-reporting of a Rare Entity.

Indian Dermatol Online J 2019 Jan-Feb;10(1):58-60

Department of Dermatology, Armed Forces Medical College, Pune, Maharashtra, India.

Rhupus syndrome, a rare entity, is the co-existence of systemic lupus erythematosus (SLE) with rheumatoid arthritis (RA). It manifests as more RA and less SLE related damages. The duration of the disease is longer than typical RA or SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_55_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362750PMC
February 2019

The Immunology of Macrophage Activation Syndrome.

Front Immunol 2019 1;10:119. Epub 2019 Feb 1.

Pediatric Rheumatology, University of Alabama Birmingham, Birmingham, AL, United States.

Synonymous with secondary hemophagocytic lymphohistiocytosis, macrophage activation syndrome (MAS) is a term used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE). Clinical and laboratory features of MAS include sustained fever, hyperferritinemia, pancytopenia, fibrinolytic coagulopathy, and liver dysfunction. Soluble interleukin-2 receptor alpha chain (sCD25) and sCD163 may be elevated, and histopathology often reveals characteristic increased hemophagocytic activity in the bone marrow (and other tissues), with positive CD163 (histiocyte) staining. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367262PMC
February 2019

Sjögren's syndrome and systemic lupus erythematosus: links and risks.

Open Access Rheumatol 2019 29;11:33-45. Epub 2019 Jan 29.

Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil,

Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) may coexist, and they are chronic complex disorders, with an autoimmune background, multifactorial etiology, multiple circulating autoantibodies, and variable prognosis. The prominent feature of SS is the impairment of the lacrimal and salivary glands leading to sicca symptoms. This disease may be classified as primary Sjögren's syndrome (pSS), or secondary Sjögren's syndrome (sSS) since it is often associated to other autoimmune disorders, principally SLE, rheumatoid arthritis, and systemic sclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OARRR.S167783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357904PMC
January 2019

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation.

J Vis Exp 2019 Jan 29(143). Epub 2019 Jan 29.

Department of Nephrology, Leiden University Medical Center;

Neutrophil extracellular traps (NETs) are immunogenic extracellular DNA structures that can be released by neutrophils upon a wide variety of triggers. NETs have been demonstrated to serve as an important host defense mechanism that traps and kills microorganisms. On the other hand, they have been implicated in diverse systemic autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/59150DOI Listing
January 2019

Genetic polymorphisms near IL-21 gene associated with Th17 cytokines confer risk for systemic lupus erythematosus in Chinese Han population.

Lupus 2019 Feb 18:961203319829821. Epub 2019 Feb 18.

1 Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.

Objective: Interleukin-21 (IL-21) contributes to expansion, differentiation, and modulation of various immunocompetent cells. Deregulated production of IL-21 plays a role of cardinal significance in the pathogenesis of systemic lupus erythematosus (SLE). We aimed to determine whether single nucleotide polymorphisms (SNP) near the IL-21 gene have significant association with SLE susceptibility and the T helper-related inflammatory cytokine profile of SLE patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319829821DOI Listing
February 2019

The study of interactions between genome and exposome in the development of systemic lupus erythematosus.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Denmark.. Electronic address:

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease characterized by a broad spectrum of clinical and serological manifestations. This may reflect a complex and multifactorial etiology involving several identified genetic and environmental factors, though not explaining the full risk of SLE. Established SLE risk genotypes are either very rare or with modest effect sizes and twin studies indicate that other factors besides genetics must be operative in SLE etiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.005DOI Listing
February 2019

Juvenile polyautoimmunity in a rheumatology setting.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.. Electronic address:

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.006DOI Listing
February 2019
1 Read

Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia.

Autoimmun Rev 2019 Feb 14. Epub 2019 Feb 14.

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo (USP), Brazil.

Objective: Recently, two studies demonstrated that a relevant percentage of primary antiphospholipid syndrome (PAPS) patients had an upregulation of interferon (IFN) genes. However, 20%-28% of these patients had anti-dsDNA, a highly specific systemic lupus erythematosus (SLE) autoantibody. This study aimed to determine the prevalence of the type I IFN signature in the peripheral blood mononuclear cells of PAPS patients without specific SLE autoantibodies and search for its clinical associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.11.004DOI Listing
February 2019

The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology.

Immunobiology 2019 Feb 8. Epub 2019 Feb 8.

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Engineering Technology Research Center of Anti-inflammatory and Immunodrugs in Anhui Province, Hefei, Anhui Province, People's Republic of China. Electronic address:

Traditionally, chemokine immunobiology has focused on chemotaxis and the positioning of cells at sites of inflammation and within lymphoid organs. More recently, however, regulation of intricate immune responses has emerged as a function attributed to chemokines and their receptors. One such pair, CCR6 and its chemokine ligand CCL20, has been receiving interest for its potential role in the coordination and regulation of humoral immune responses and in particular, memory responses, at the cellular level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imbio.2019.01.005DOI Listing
February 2019
1 Read

Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus.

Arthritis Rheumatol 2019 Feb 16. Epub 2019 Feb 16.

Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.

Objective: To evaluate the properties of a frailty index (FI), constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, as a novel health measure in SLE.

Methods: For this secondary analysis, the baseline visit was defined as the first study visit at which both organ damage (SLICC/ACR Damage Index [SDI]) and health-related quality of life (Short-Form 36 [SF-36]) were assessed. The SLICC-FI was constructed using baseline data. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/art.40859
Publisher Site
http://dx.doi.org/10.1002/art.40859DOI Listing
February 2019
2 Reads

Safety and efficacy of belimumab plus standard therapy for up to 13 years in patients with systemic lupus erythematosus.

Arthritis Rheumatol 2019 Feb 16. Epub 2019 Feb 16.

GSK, Raleigh-Durham, NC, USA.

Objective: Investigate long-term safety and efficacy of intravenous (IV) belimumab plus standard systemic lupus erythematosus (SLE) therapy (SoC) in active, autoantibody-positive SLE.

Methods: This was a multicenter, open-label, continuation study of IV belimumab given every four weeks with SoC in patients with SLE who completed a Phase II, double-blind study. Adverse events (AEs) and laboratory data were monitored from the first belimumab dose (in either study) until 24 weeks after the final dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40861DOI Listing
February 2019
1 Read

The skewed frequency of B-cell subpopulation CD19 CD24 CD38 cells in peripheral blood mononuclear cells is correlated with the elevated serum sCD40L in patients with active systemic lupus erythematosus.

J Cell Biochem 2019 Feb 16. Epub 2019 Feb 16.

Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.

CD19 CD24 CD38 cells play an essential role in maintaining immune homeostasis. CD40 signaling is involved in regulating the induction and function of CD19 CD24 CD38 cells. Changes in B-cell subpopulations and CD19 CD24 CD38 cells have been observed in systemic lupus erythematosus (SLE) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28427DOI Listing
February 2019
1 Read

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.

Arthritis Res Ther 2019 Feb 15;21(1):61. Epub 2019 Feb 15.

Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.

Background: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and the involvement of multiple internal organs. Previous studies reported poorer health-related quality of life (HRQoL) in patients with SSc compared with the general population. However, very little is known about how HRQoL in SSc patients compares with that in patients with other systemic autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjogren's syndrome (SjS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1842-xDOI Listing
February 2019
1 Read

Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From the Division of Rheumatology, The Hospital for Sick Children; Faculty of Medicine, University of Toronto; Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada. J.J. Tao, BSc, Division of Rheumatology, The Hospital for Sick Children, and Faculty of Medicine, University of Toronto, and Translational Medicine, SickKids Research Institute; L.T. Hiraki, MD, FRCPC, ScD, Division of Rheumatology, The Hospital for Sick Children, and Faculty of Medicine, University of Toronto, and Translational Medicine, SickKids Research Institute; D.M. Levy, MD, FRCPC, Division of Rheumatology, The Hospital for Sick Children, and Faculty of Medicine, University of Toronto, and Translational Medicine, SickKids Research Institute; E.D. Silverman, MD, FRCPC, Division of Rheumatology, The Hospital for Sick Children, and Faculty of Medicine, University of Toronto, and Translational Medicine, SickKids Research Institute. Address correspondence to Dr. E.D. Silverman, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. E-mail: Accepted for publication October 4, 2018.

Objective: Currently there are 2 different classification criteria for systemic lupus erythematosus (SLE): American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (cSLE) using a large, multiethnic cohort.

Methods: We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180337DOI Listing
February 2019
1 Read

Practice-Based Differences in Pediatric Discoid Lupus Erythematosus.

Br J Dermatol 2019 Feb 15. Epub 2019 Feb 15.

Northwestern University Feinberg School of Medicine, Department of Dermatology and Pediatrics, Chicago, Illinois, United States.

Background: Children with discoid lupus erythematosus (DLE) are at risk for disfigurement and progression to systemic lupus erythematosus (SLE). Consensus is lacking regarding optimal care of children with DLE.

Objectives: We compared practice patterns among pediatric dermatologists/rheumatologists treating pediatric DLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17780DOI Listing
February 2019
1 Read

Patient Perspectives on Smoking Cessation and Interventions in Rheumatology Clinics.

Arthritis Care Res (Hoboken) 2019 Feb 15. Epub 2019 Feb 15.

UW-SMPH Department of Medicine, Rheumatology, Madison, WI, United States.

Objective: Although smoking is a risk factor for cardiovascular and rheumatic disease severity, only 10% of rheumatology visits document cessation counseling. After implementing a rheumatology clinic protocol that increased tobacco quitline referrals 20-fold, current objectives were to 1) examine patients' barriers and facilitators to smoking cessation based on prior rheumatology experiences, 2) solicit reactions to the new cessation protocol, and 3) identify patient-centered outcomes or "signs of cessation progress" following improved care.

Methods: We recruited 19 patients who smoke-12 with rheumatoid arthritis (RA) and 7 with systemic lupus erythematosus (SLE)-to one of three semi-structured focus groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23858DOI Listing
February 2019
1 Read

Hsp70 Gene Polymorphisms Are Associated With Disease Susceptibility and HRQOL Improvement in Chinese Han Population With Systemic Lupus Erythematosus.

J Clin Rheumatol 2019 Feb 13. Epub 2019 Feb 13.

Department of Biochemistry and Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, Anhui, China.

Objectives: The aim of this study is to investigate whether heat shock protein 70 (Hsp70) gene polymorphisms are implicated in systemic lupus erythematous (SLE) susceptibility, the efficacy of glucocorticoids (GCs) treatment, and improvement of health-related quality of life.

Methods: A total of 499 SLE patients and 499 controls were included in a case-control study, and 468 SLE patients treated with GCs for 12 weeks were involved in a follow-up study. Patients who completed the 12-week follow-up were divided into GCs-sensitive and GCs-insensitive group by using the SLE disease activity index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000986DOI Listing
February 2019
1 Read
1.245 Impact Factor

Gp49B is a pathogenic marker for autoantibody-producing plasma cells in lupus-prone BXSB/Yaa mice.

Int Immunol 2019 Feb 15. Epub 2019 Feb 15.

Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Immune homeostasis is critically regulated by the balance between activating and inhibitory receptors expressed on various immune cells such as T and B lymphocytes, and myeloid cells. The inhibitory receptors play a fundamental role in the immune-checkpoint pathway, thus maintaining peripheral tolerance. We recently found that expression of leukocyte immunoglobulin-like receptor (LILR)B4, an inhibitory member of the human LILR family, is augmented in autoantibody-producing plasmablasts/plasma cells of systemic lupus erythematosus (SLE) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxz017DOI Listing
February 2019
1 Read
2.536 Impact Factor

Serum osteopontin negatively impacts on intima media thickness in patients with SLE.

Eur J Clin Invest 2019 Feb 14:e13089. Epub 2019 Feb 14.

IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascolar Network, 10 largo Benzi, 16132, Genoa, Italy.

Background: Ultrasound evaluation of carotid intima media thickness (cIMT) has been extensively used for potentially improving cardiovascular (CV) risk stratification in several patients' categories. Subjects with systemic lupus erythematosus (SLE) have been investigated by both imaging and molecular biomarker approaches with contrasting results. Here, we focused on the role of osteopontin (OPN) as biomarker of subclinical atherosclerosis associated with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/eci.13089DOI Listing
February 2019
1 Read

Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus.

Clin Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

Section of Rheumatology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.

Elevated IL-17 levels with higher Th17 numbers are identified in systemic lupus erythematosus (SLE). STAT3 signaling plays a crucial role in the Th17 generation, and SOCS3 negatively regulates their formation. We investigated IL-17, STAT3, and SOCS3 expression, and analyzed their correlations to elucidate the regulatory mechanisms of IL-17 production in SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04467-8DOI Listing
February 2019
1 Read

Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy.

BMC Ophthalmol 2019 Feb 14;19(1):51. Epub 2019 Feb 14.

Department of Ophthalmology, University of Kansas School of Medicine, 7400 State Line Rd, Prairie Village, Kansas, USA.

Background: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy.

Case Presentation: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendronic acid infusion. She has a past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren's syndrome, and systemic lupus erythematosus that have been controlled with immunosuppressive therapy for three years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-019-1063-8DOI Listing
February 2019
1 Read

Long-term and high dose dexamethasone injection decreases the expression of Immunoglobulin Heavy (Light) Chain Variable Region Genes (IGH(L)Vs) in the mouse spleen.

Gene 2019 Feb 11;695:42-50. Epub 2019 Feb 11.

The M.O.E. Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, PR China. Electronic address:

Glucocorticoid hormones have been widely used in clinical practice as potent anti-inflammatory and immunosuppressive agents. However, the underlying mechanisms of how they work remain unaddressed. Here, we used RNA-set to profile spleen gene expression in adult mice after consistent intraperitoneal injection of dexamethasone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2019.01.047DOI Listing
February 2019
1 Read

Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study.

J Am Acad Dermatol 2019 Feb 11. Epub 2019 Feb 11.

Dermatology - Department Medical Science and Public Health, University of Cagliari, Via Ospedale 54, 09124 Cagliari Italy; European Academy of Dermatology and Venereology (EADV) Task Force of Dermatopathology; SIDEMAST Dermatopathology Study Group of Italian Society of Dermatology.

Background: Clinical and pathological criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial.

Objective: Aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathological investigation.

Methods: Eleven European University Dermatology Units collected all diagnosed cases from January 2000 to December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.009DOI Listing
February 2019
1 Read
4.449 Impact Factor

Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus.

Autoimmun Rev 2019 Feb 11. Epub 2019 Feb 11.

Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunología Celular e Inmunogenética-GICIG, Medellín, Colombia.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that can involve nervous system commitment known as neuropsychiatric systemic lupus erythematosus (NPSLE). The diagnostic of NPSLE is complex because the symptoms range from focal symptoms (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.12.004DOI Listing
February 2019

Conceptual, statistical and clinical interpretation of results from a systematic review and meta-analysis of prevalence of cervical HPV infection in women with SLE.

Autoimmun Rev 2019 Feb 11. Epub 2019 Feb 11.

The University of Adelaide, North Terrace Campus, Adelaide, South Australia 5005, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193003
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.12.003DOI Listing
February 2019
2 Reads

Abnormal retinal microvasculature found in active rheumatoid arthritis:a different perspective of microvascular health

Turk J Med Sci 2019 Feb 11;49(1):20-26. Epub 2019 Feb 11.

Background/aim: We aimed to assess the association between retinal vascular caliber (RVC) scores and disease activity in rheumatoid arthritis (RA) patients.

Materials And Methods: Forty-seven RA patients, 32 systemic lupus erythematosus (SLE) patients, and 45 healthy people were enrolled. RA and SLE patients were subdivided into groups according to C-reactive protein (CRP) levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1806-1DOI Listing
February 2019
1 Read

Autoantibodies Against C3b-Functional Consequences and Disease Relevance.

Front Immunol 2019 29;10:64. Epub 2019 Jan 29.

INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

The complement component C3 is at the heart of the complement cascade. It is a complex protein, which generates different functional activated fragments (C3a, C3b, iC3b, C3c, C3d). C3b is a constituent of the alternative pathway C3 convertase (C3bBb), binds multiple regulators, and receptors, affecting thus the functioning of the immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361862PMC
January 2019
1 Read

Evolving and expanding scope of lupus-inducing drugs.

Authors:
Robert L Rubin

Ann Rheum Dis 2019 Feb 13. Epub 2019 Feb 13.

Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214785DOI Listing
February 2019
1 Read

Antibodies to M-type phospholipase A2 receptor (PLAR) in membranous lupus nephritis.

Lupus 2019 Feb 13:961203319828521. Epub 2019 Feb 13.

1 Department of Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebrón, Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: Antibodies to M-type phospholipase A2 receptor (a-PLAR) have been identified in most patients with idiopathic membranous nephropathy, but the prevalence in membranous lupus nephritis (MLN) is still unclear. The objective of this study was to assess the prevalence of a-PLAR antibodies in a large cohort of patients with lupus nephritis.

Methods: a-PLAR antibodies were measured by ELISA in serum from patients with systemic lupus erythematosus ( n = 190), of whom 37 had a biopsy-proven MLN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319828521DOI Listing
February 2019
6 Reads

Downregulation of miR-633 activated AKT/mTOR pathway by targeting AKT1 in lupus CD4 T cells.

Lupus 2019 Feb 13:961203319829853. Epub 2019 Feb 13.

1 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Background: Accumulating evidence suggests that the AKT/mTOR pathway plays an important role in the pathogenesis of systemic lupus erythematosus (SLE) through activating T cells, and there are few studies looking into the role of microRNA (miRNAs) in the mechanism. We first found that miR-633 expression in CD4T cells of SLE patients was significantly reduced.

Objective: To investigate the role of miR-633 in the AKT/mTOR pathway in lupus CD4T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319829853DOI Listing
February 2019
1 Read

Dnase1-deficient mice spontaneously develop a systemic lupus erythematosus-like disease.

Eur J Immunol 2019 Feb 13. Epub 2019 Feb 13.

Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany.

Systemic lupus erythematosus (SLE) is an autoimmune disease that has high morbidity and can result in multi-organ damage. SLE is characterized by dysregulated activation of T- and B-lymphocytes and the production of autoantibodies directed against nuclear components. The endonuclease deoxyribonuclease 1 (DNase1) is abundant in blood and a subset of SLE patients have mutations in DNASE1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201847875DOI Listing
February 2019
1 Read

Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features.

Biomed Res Int 2019 10;2019:2437105. Epub 2019 Jan 10.

Rheumatology Department, Faculty of Medicine, Cairo University, Giza, Egypt.

Objectives: This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases.

Methods: The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2437105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348873PMC
January 2019
6 Reads

Use of Intravenous Immunoglobulin Therapy at Unconventional Doses in Refractory Fulminant Systemic Lupus Erythematosus.

Eur J Case Rep Intern Med 2018 27;5(9):000934. Epub 2018 Sep 27.

Rare Diseases and Periodic Fevers Research Centre, Department of Internal Medicine, Agostino Gemelli University Hospital Foundation, Catholic University of the Sacred Heart, Rome, Italy.

The use of human intravenous immunoglobulins (IVIg) in systemic lupus erythematosus (SLE) currently relies on evidence from small case series and is mainly regarded as an off-label strategy in cases that are refractory to conventional therapies or poorly controlled with high doses of corticosteroids. Standard dosage regimens typically entail the administration of a total amount of 2 g/kg of IVIg divided into five consecutive days in order to minimize the risk of severe adverse events. We herein describe the case of a 28-year-old woman with a known history of antiphospholipid syndrome (APS) who was admitted to our hospital following fulminant onset of SLE in spite of ongoing immunosuppressive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346821PMC
September 2018
1 Read

Kikuchi-Fujimoto Disease Associated with Sjögren's Syndrome: A Case Report.

Eur J Case Rep Intern Med 2018 25;5(5):000856. Epub 2018 May 25.

Rheumatology Department, Hamad Medical Corporation, Doha, Qatar.

Kikuchi-Fujimoto disease (KFD) or Kikuchi histiocytic necrotizing lymphadenitis, is an extremely rare, benign and self-limiting disease which can be confused with lymphoma and sometime with infections such as tuberculosis. It has also been infrequently reported in association with autoimmune diseases. KFD shares sex and age predisposition as well as histological features with systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000856DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346929PMC
May 2018
3 Reads

Prediction of fetal loss in Chinese pregnant patients with systemic lupus erythematosus: a retrospective cohort study.

BMJ Open 2019 Feb 11;9(2):e023849. Epub 2019 Feb 11.

Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Objective: To develop a predictive model for fetal loss in women with systemic lupus erythematosus (SLE).

Design: A retrospective cohort study.

Setting: Data were collected in a tertiary medical centre, located in Shanghai, China, from September 2011 to May 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-023849DOI Listing
February 2019
2 Reads

Posterior reversible encephalopathy syndrome due to hypercalcaemia: a rare cause.

BMJ Case Rep 2019 Feb 11;12(2). Epub 2019 Feb 11.

Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity described by Hinchey in late 90's, characterised by variable associations of seizure activity, consciousness impairment ranging from confusion to coma, headaches, visual abnormalities, nausea/vomiting and focal neurological signs. Common causes are accelerated hypertension, eclampsia, preeclampsia, cytotoxic drug use and autoimmune diseases like systemic lupus erythematosus.We report a case of PRES in a 62-year-old female patient due to hypercalcemia secondary to vitamin D toxicity on treatment with calcium supplements and vitamin D for secondary hypoparathyroidism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-223415DOI Listing
February 2019
3 Reads